| Date:2021-12-22   |
|---|
| Your Name:Zhixian Zhong   |
| Manuscript Title:Sintilimab treatment for ureteral carcinoma following bladder cancer leads to leukopenia: a case |
| report  |
| Manuscript number (if known):   |
|   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5       Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events      None         6       Payment for expert<br>testimony      None         7       Support for attending<br>meetings and/or travel      None         8       Patents planned, issued or<br>pending      None         9       Patricipation on a Data<br>Safety Monitoring Board or<br>Advisory Board      None         10       Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services      None         13       Other financial or non-<br>financial interests      None |    |                              |      |  |
|---|----|------------------------------|------|--|
| lectures, presentations, speakers bureaus, manuscript writing or educational events   |    |                              |      |  |
| speakers bureaus,<br>manuscript writing or<br>educational events  | 5  | Payment or honoraria for     | None |  |
| manuscript writing or<br>educational events   |    | lectures, presentations,     |      |  |
| educational events  |    | speakers bureaus,            |      |  |
| educational events  |    | -                            |      |  |
| 6       Payment for expert testimony  |    |                              |      |  |
| testimony   | 6  |                              | None |  |
| 7       Support for attending meetings and/or travel      None         8       Patents planned, issued or pending      None         9       Participation on a Data Safety Monitoring Board or Advisory Board      None         10       Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None   | 0  |                              |      |  |
| meetings and/or travel  |    | testimony                    |      |  |
| meetings and/or travel  | _  |                              |      |  |
| 8       Patents planned, issued or pending  | 7  |                              | None |  |
| pending   |    | meetings and/or travel       |      |  |
| pending   |    |                              |      |  |
| pending   |    |                              |      |  |
| pending   |    |                              |      |  |
| pending   | 0  | Patents planned issued or    | Nono |  |
| 9       Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board      None         10       Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services      None         13       Other financial or non-      None   | 0  |                              |      |  |
| Safety Monitoring Board or<br>Advisory Board  |    | pending                      |      |  |
| Safety Monitoring Board or<br>Advisory Board  |    |                              |      |  |
| Advisory Board  | 9  |                              | None |  |
| 10       Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid      None         11       Stock or stock options      None         11       Stock or stock options      None         12       Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services      None         13       Other financial or non-      None   |    |                              |      |  |
| in other board, society, committee or advocacy group, paid or unpaid  |    | Advisory Board               |      |  |
| committee or advocacy   | 10 | Leadership or fiduciary role | None |  |
| group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None  |    | in other board, society,     |      |  |
| 11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None  |    | committee or advocacy        |      |  |
| 11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None  |    | group, paid or unpaid        |      |  |
| 12     Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services    None       13     Other financial or non-    None   | 11 |                              | None |  |
| materials, drugs, medical   |    |                              |      |  |
| materials, drugs, medical   |    |                              |      |  |
| materials, drugs, medical   | 12 | Possint of aquinment         | Nono |  |
| writing, gifts or other<br>services   | 12 |                              |      |  |
| services       13     Other financial or non-   None  |    |                              |      |  |
| 13   Other financial or non-  None  |    |                              |      |  |
|   |    |                              |      |  |
| financial interests   | 13 |                              | None |  |
|   |    | financial interests          |      |  |
|   |    |                              |      |  |

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

| Date:2021-12-22   |
|---|
| Your Name:Zhiying Wang  |
| Manuscript Title:Sintilimab treatment for ureteral carcinoma following bladder cancer leads to leukopenia: a case |
| report  |
| Manuscript number (if known):   |
|   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5       Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events      None         6       Payment for expert<br>testimony      None         7       Support for attending<br>meetings and/or travel      None         8       Patents planned, issued or<br>pending      None         9       Patricipation on a Data<br>Safety Monitoring Board or<br>Advisory Board      None         10       Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services      None         13       Other financial or non-<br>financial interests      None |    |                              |      |  |
|---|----|------------------------------|------|--|
| lectures, presentations, speakers bureaus, manuscript writing or educational events   |    |                              |      |  |
| speakers bureaus,<br>manuscript writing or<br>educational events  | 5  | Payment or honoraria for     | None |  |
| manuscript writing or<br>educational events   |    | lectures, presentations,     |      |  |
| educational events  |    | speakers bureaus,            |      |  |
| educational events  |    | -                            |      |  |
| 6       Payment for expert testimony  |    |                              |      |  |
| testimony   | 6  |                              | None |  |
| 7       Support for attending meetings and/or travel      None         8       Patents planned, issued or pending      None         9       Participation on a Data Safety Monitoring Board or Advisory Board      None         10       Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None   | 0  |                              |      |  |
| meetings and/or travel  |    | testimony                    |      |  |
| meetings and/or travel  | _  |                              |      |  |
| 8       Patents planned, issued or pending  | 7  |                              | None |  |
| pending   |    | meetings and/or travel       |      |  |
| pending   |    |                              |      |  |
| pending   |    |                              |      |  |
| pending   |    |                              |      |  |
| pending   | 0  | Patents planned issued or    | Nono |  |
| 9       Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board      None         10       Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services      None         13       Other financial or non-      None   | 0  |                              |      |  |
| Safety Monitoring Board or<br>Advisory Board  |    | pending                      |      |  |
| Safety Monitoring Board or<br>Advisory Board  |    |                              |      |  |
| Advisory Board  | 9  |                              | None |  |
| 10       Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid      None         11       Stock or stock options      None         11       Stock or stock options      None         12       Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services      None         13       Other financial or non-      None   |    |                              |      |  |
| in other board, society, committee or advocacy group, paid or unpaid  |    | Advisory Board               |      |  |
| committee or advocacy   | 10 | Leadership or fiduciary role | None |  |
| group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None  |    | in other board, society,     |      |  |
| 11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None  |    | committee or advocacy        |      |  |
| 11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None  |    | group, paid or unpaid        |      |  |
| 12     Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services    None       13     Other financial or non-    None   | 11 |                              | None |  |
| materials, drugs, medical   |    |                              |      |  |
| materials, drugs, medical   |    |                              |      |  |
| materials, drugs, medical   | 12 | Possint of aquinment         | Nono |  |
| writing, gifts or other<br>services   | 12 |                              |      |  |
| services       13     Other financial or non-   None  |    |                              |      |  |
| 13   Other financial or non-  None  |    |                              |      |  |
|   |    |                              |      |  |
| financial interests   | 13 |                              | None |  |
|   |    | financial interests          |      |  |
|   |    |                              |      |  |

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

| Date:  | 2021-12-22  |
|--------|---|
| Your M | Name:Yun Li   |
| Manu   | script Title:Sintilimab treatment for ureteral carcinoma following bladder cancer leads to leukopenia: a case |
| report |   |
| Manu   | script number (if known):   |
|        |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5       Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events      None         6       Payment for expert<br>testimony      None         7       Support for attending<br>meetings and/or travel      None         8       Patents planned, issued or<br>pending      None         9       Patricipation on a Data<br>Safety Monitoring Board or<br>Advisory Board      None         10       Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services      None         13       Other financial or non-<br>financial interests      None |    |                              |      |  |
|---|----|------------------------------|------|--|
| lectures, presentations, speakers bureaus, manuscript writing or educational events   |    |                              |      |  |
| speakers bureaus,<br>manuscript writing or<br>educational events  | 5  | Payment or honoraria for     | None |  |
| manuscript writing or<br>educational events   |    | lectures, presentations,     |      |  |
| educational events  |    | speakers bureaus,            |      |  |
| educational events  |    | -                            |      |  |
| 6       Payment for expert testimony  |    |                              |      |  |
| testimony   | 6  |                              | None |  |
| 7       Support for attending meetings and/or travel      None         8       Patents planned, issued or pending      None         9       Participation on a Data Safety Monitoring Board or Advisory Board      None         10       Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None   | 0  |                              |      |  |
| meetings and/or travel  |    | testimony                    |      |  |
| meetings and/or travel  | _  |                              |      |  |
| 8       Patents planned, issued or pending  | 7  |                              | None |  |
| pending   |    | meetings and/or travel       |      |  |
| pending   |    |                              |      |  |
| pending   |    |                              |      |  |
| pending   |    |                              |      |  |
| pending   | 0  | Patents planned issued or    | Nono |  |
| 9       Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board      None         10       Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services      None         13       Other financial or non-      None   | 0  |                              |      |  |
| Safety Monitoring Board or<br>Advisory Board  |    | pending                      |      |  |
| Safety Monitoring Board or<br>Advisory Board  |    |                              |      |  |
| Advisory Board  | 9  |                              | None |  |
| 10       Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid      None         11       Stock or stock options      None         11       Stock or stock options      None         12       Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services      None         13       Other financial or non-      None   |    |                              |      |  |
| in other board, society, committee or advocacy group, paid or unpaid  |    | Advisory Board               |      |  |
| committee or advocacy   | 10 | Leadership or fiduciary role | None |  |
| group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None  |    | in other board, society,     |      |  |
| group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None  |    | committee or advocacy        |      |  |
| 11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None  |    | group, paid or unpaid        |      |  |
| 12     Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services    None       13     Other financial or non-    None   | 11 |                              | None |  |
| materials, drugs, medical   |    |                              |      |  |
| materials, drugs, medical   |    |                              |      |  |
| materials, drugs, medical   | 12 | Possint of aquinment         | Nono |  |
| writing, gifts or other<br>services   | 12 |                              |      |  |
| services       13     Other financial or non-   None  |    |                              |      |  |
| 13   Other financial or non-  None  |    |                              |      |  |
|   |    |                              |      |  |
| financial interests   | 13 |                              | None |  |
|   |    | financial interests          |      |  |
|   |    |                              |      |  |

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

| Date:  | 2021-12-22  |
|--------|---|
| Your l | Name:Yi Zhong   |
|        | script Title:Sintilimab treatment for ureteral carcinoma following bladder cancer leads to leukopenia: a case |
| report |   |
| Manu   | script number (if known):   |
|        |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | Time frame: Since the initialNone  | planning of the work  |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| r  |                              |      |  |
|----|------------------------------|------|--|
|    |                              |      |  |
| 5  | Payment or honoraria for     | None |  |
|    | lectures, presentations,     |      |  |
|    | speakers bureaus,            |      |  |
|    | manuscript writing or        |      |  |
|    | educational events           |      |  |
| 6  | Payment for expert           | None |  |
| 0  | testimony                    |      |  |
|    | testimony                    |      |  |
| _  |                              |      |  |
| 7  | Support for attending        | None |  |
|    | meetings and/or travel       |      |  |
|    |                              |      |  |
|    |                              |      |  |
|    |                              |      |  |
| 8  | Patents planned, issued or   | None |  |
| 0  | pending                      |      |  |
|    | pending                      |      |  |
| -  |                              |      |  |
| 9  | Participation on a Data      | None |  |
|    | Safety Monitoring Board or   |      |  |
|    | Advisory Board               |      |  |
| 10 | Leadership or fiduciary role | None |  |
|    | in other board, society,     |      |  |
|    | committee or advocacy        |      |  |
|    | group, paid or unpaid        |      |  |
| 11 | Stock or stock options       | None |  |
|    |                              |      |  |
|    |                              |      |  |
| 12 | Receipt of equipment,        | None |  |
| 12 | materials, drugs, medical    |      |  |
|    |                              |      |  |
|    | writing, gifts or other      |      |  |
| 10 | services                     |      |  |
| 13 | Other financial or non-      | None |  |
|    | financial interests          |      |  |
|    |                              |      |  |
|    |                              |      |  |

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement: